Too big a gamble for the shorts to ride it out. Safety is not an issue since there are other similar products on the market. What benefit is there? Transdermal (AIS) technology is more advanced no needles, no topical gel which can be absorbed by the partner. This is why there is such a strong belief it will get approved. Playing the devil's advocate. There may be a slight pull back if not approved but BPAX is still grossly undervalued that the price will continue to climb, it just might take a little longer.
If you are concerned look at what other company's are trading at and look at their pipeline. I put it together for those new to BPAX and to show the fire the shorts are playing with.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.